Patient-level Factors Associated With the Initial Management of Older Adults Diagnosed With Follicular Lymphoma: A Surveillance, Epidemiology, and End Results–Medicare Analysis

ConclusionThe present analysis identifies disparities in the initial management of older adults with FL owing to race and socioeconomic status. Future research should examine implications for subsequent treatment and health outcomes.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research

Related Links:

We retrospectively analyzed 48 CNS lymphoma patients who received HDC/ASCT using TBC conditioning. We found a 2-year PFS and OS rate of 80.5% and 80.1%, respectively. Toxicities included nausea/vomiting, diarrhea, mucositis, and febrile neutropenia. Treatment-related mortality was 8.3% in the first 100 days post-transplant. This data supports the use of consolidative ASCT in PCNSL and secondary CNS lymphoma patients.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Publication date: Available online 15 February 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Alan Burnett, Richard StoneAbstractDespite the approval of 8 new drugs for AML since 2017, the disease remains challenging given the significant toxicity associated with available treatments and relatively low cure rates, especially in older adults. While advantageous for patients, self-congratulatory rejoicing about the new agents would be extremely premature. Questions abound about the need for a specific vs less specific FLT3 inhibitor (e.g midostautin) in the upfront setting and whether a single agent (gilteritni...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionED remains a major problem in APL patients, especially in a real-life population. Shortening of the time between the initial contact with a health care professional, and all-trans retinoic acid administration and the use of appropriate supportive care could improve the outcome of unselected APL population, mainly by reducing the ED rate.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionsIn the largest real-world study, we demonstrate an association between factors such as age, comorbidity and AML subtypes, and the use of multiagent chemotherapy. The use of multiagent chemotherapy was associated with improved OS, particularly among patients younger than 70 years, good-risk AML and those with low Charlson comorbidity score.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionsDespite several limitations affect this analysis, especially related to the heterogeneity of the studies included, MCL is an 18F-FDG-avid lymphoma in most of the cases, with the exception of BM and GI disease. Moreover, 18F-FDG PET/CT seems to be useful in evaluating treatment response and prognosis.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
We analyzed US National Cancer Data Base of patients aged 60-79 years, who were diagnosed with acute myeloid leukemia (AML) between 2004-2014 (n=25,621). The use of multiagent versus single-agent chemotherapy was associated with a greater 1-year overall survival (43% vs. 28%), particularly for patients aged 60-69 years, those with good-risk AML or Charlson comorbidity score of 0-1.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Paraneoplastic cholestasis is a rare manifestation of Hodgkin ’s lymphoma (HL), especially in the relapsed/refractory setting. Outcomes are generally poor, perhaps related to the narrow therapeutic window of standard chemotherapy drugs in patients with compromised liver function and limited activity of radiotherapy in controlling systemic disease. Here, we p resent the first report of successful treatment of a patient with idiopathic cholestasis in the setting of relapsed HL post autologous stem cell transplant (ASCT) with bridging therapy (cyclophosphamide, methylprednisolone) and sequential nivolumab.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research
ConclusionOur study did not find a statistically significant difference in the overall response rates or survival outcome measures for patients with AML and indeterminate day 14 bone marrow in the 2 treatment groups. Our findings question the utility of immediate reinduction chemotherapy and raise concern regarding overtreatment in this patient population. Larger studies investigating similar outcomes are warranted to validate our clinical findings.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionsThe high ORR and reasonable duration of response could allow for potentially curative allogeneic hematopoietic cell transplantation for these patients with high-risk AML. Our initial data suggest that lenalidomide plus HMA is a promising approach for patients with AML with inv(3).
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionsThis is the first multicenter report analyzing AML-survival in Mexico. Challenges in this setting include a high induction-related mortality and low AlloHSCT rate, which should be addressed in order to improve outcomes.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Chemotherapy | Epidemiology | Leukemia | Lymphoma | Medicare | Myeloma | Rituxan